Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Guardant Health, Inc. (GH)

24.33   0.15 (0.62%) 03-27 16:00
Open: 24.5 Pre. Close: 24.18
High: 24.89 Low: 23.895
Volume: 1,311,468 Market Cap: 2,498(M)

Technical analysis

as of: 2023-03-27 4:19:38 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 33.97     One year: 38.2
Support: Support1: 23.21    Support2: 19.31
Resistance: Resistance1: 29.08    Resistance2: 32.7
Pivot: 26.45
Moving Average: MA(5): 24.93     MA(20): 27.54
MA(100): 35.04     MA(250): 44.19
MACD: MACD(12,26): -1.4     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 11.1     %D(3): 12
RSI: RSI(14): 37.7
52-week: High: 77.72  Low: 23.21
Average Vol(K): 3-Month: 2,023 (K)  10-Days: 2,272 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GH ] has closed above bottom band by 17.9%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 24.42 - 24.62 24.62 - 24.75
Low: 22.82 - 23.03 23.03 - 23.18
Close: 23.89 - 24.23 24.23 - 24.46

Company Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Headline News

Tue, 21 Mar 2023
Guardant Health collaborates with The Ohio State University ... - Business Wire

Thu, 16 Mar 2023
Guru Fundamental Report for GH - Nasdaq

Mon, 13 Mar 2023
Two Sigma Investments LP Lowers Holdings in Guardant Health, Inc ... - MarketBeat

Fri, 10 Mar 2023
Guardant Health submits premarket approval application to the U.S. ... - Business Wire

Thu, 09 Mar 2023
EXAS stock upgraded, GH stock downgraded at Citi diagnostics ... - Seeking Alpha

Thu, 09 Mar 2023
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 103 (M)
Shares Float 98 (M)
% Held by Insiders 4.6 (%)
% Held by Institutions 91.6 (%)
Shares Short 7,000 (K)
Shares Short P.Month 5,530 (K)

Stock Financials

EPS -6.72
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.58
Profit Margin (%) -145.7
Operating Margin (%) -121.1
Return on Assets (ttm) -17.9
Return on Equity (ttm) -185.7
Qtrly Rev. Growth 17.3
Gross Profit (p.s.) 2.85
Sales Per Share 4.37
EBITDA (p.s.) -4.96
Qtrly Earnings Growth 0
Operating Cash Flow -309 (M)
Levered Free Cash Flow -296 (M)

Stock Valuations

PE Ratio -3.63
PEG Ratio 0.3
Price to Book value 41.23
Price to Sales 5.55
Price to Cash Flow -8.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.